In the Margins

Valeant names hedge fund partner to board

October 26, 2015

By Forbes

Valeant Pharmaceuticals has named Mason Morfit, a partner at activist hedge fund ValueAct Capital, to its board of directors. Morfit previously served on the embattled specialty drugmaker's board from 2007 to 2014; ValueAct is one of Valeant's largest shareholders. Read the original story from Forbes

 

 

Most Read

A Seat at the Table
Thrivent forms board to oversee new interval fund

Thrivent Financial is entering the interval fund business and has assembled a new board to oversee its first offering, the soon-to-be-launched Thrivent Church Loan & Income Fund. ...

Top of the Agenda - Legal
PIMCO 36(b) case dismissed

The parties in a 2014 lawsuit accusing PIMCO of overcharging Total Return Fund shareholders while lavishly compensating CIO Bill Gross and CEO Mohamed El-Erian agreed this week ...